116 related articles for article (PubMed ID: 11565320)
1. [Fibrates in the secondary prevention of ischemic cardiopathy].
Posadas Romero C
Arch Cardiol Mex; 2001; 71 Suppl 1():S139-41. PubMed ID: 11565320
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
[TBL] [Abstract][Full Text] [Related]
3. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
4. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study.
Goldbourt U; Brunner D; Behar S; Reicher-Reiss H
Eur Heart J; 1998 Jul; 19 Suppl H():H42-7. PubMed ID: 9717065
[TBL] [Abstract][Full Text] [Related]
5. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
Otvos JD; Collins D; Freedman DS; Shalaurova I; Schaefer EJ; McNamara JR; Bloomfield HE; Robins SJ
Circulation; 2006 Mar; 113(12):1556-63. PubMed ID: 16534013
[TBL] [Abstract][Full Text] [Related]
6. Role of fibrates in reducing coronary risk: a UK Consensus.
UK HDL-C Consensus Group
Curr Med Res Opin; 2004; 20(2):241-7. PubMed ID: 15006019
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
[TBL] [Abstract][Full Text] [Related]
8. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.
Goldenberg I; Boyko V; Tennenbaum A; Tanne D; Behar S; Guetta V
Arch Intern Med; 2009 Mar; 169(5):508-14. PubMed ID: 19273782
[TBL] [Abstract][Full Text] [Related]
9. Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials.
Rizos E; Mikhailidis DP
Int J Cardiol; 2002 Mar; 82(3):199-207; discussion 207-8. PubMed ID: 11911905
[TBL] [Abstract][Full Text] [Related]
10. What is the most effective strategy for managing diabetic dyslipidaemia?
Reasner CA
Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
Barter PJ; Rye KA
Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):39-46. PubMed ID: 17717290
[TBL] [Abstract][Full Text] [Related]
12. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
[TBL] [Abstract][Full Text] [Related]
13. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
[TBL] [Abstract][Full Text] [Related]
14. Low HDL-C: a secondary target of dyslipidemia therapy.
Rosenson RS
Am J Med; 2005 Oct; 118(10):1067-77. PubMed ID: 16194634
[TBL] [Abstract][Full Text] [Related]
15. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.
Ericsson CG
Eur Heart J; 1998 Jul; 19 Suppl H():H37-41. PubMed ID: 9717064
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
Jones PH
Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
[TBL] [Abstract][Full Text] [Related]
17. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).
Goldenberg I; Goldbourt U; Boyko V; Behar S; Reicher-Reiss H;
Am J Cardiol; 2006 Feb; 97(4):466-71. PubMed ID: 16461038
[TBL] [Abstract][Full Text] [Related]
18. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
19. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).
Cui Y; Watson DJ; Girman CJ; Shapiro DR; Gotto AM; Hiserote P; Clearfield MB
Am J Cardiol; 2009 Sep; 104(6):829-34. PubMed ID: 19733719
[TBL] [Abstract][Full Text] [Related]
20. Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates.
Milionis HJ; Elisaf MS; Mikhailidis DP
Curr Med Res Opin; 2000; 16(1):21-32. PubMed ID: 16422031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]